News
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
Media
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
Morning Rounds
OncView
Podcasts
Readout 360
Satellite Sessions
Sponsored Media
Training Academy
Year in Review
Conferences
Publications
All Journals
For Authors
Tumor Board
Events
Frontline Forum
CME/CE
Resources
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Subscribe
Print Subscription
eNewsletter

logo
Spotlight
Around the Practice
Between the Lines
Contemporary Concepts
Journal
OncView
Podcasts
Readout 360
2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates
CancerNetwork® Inaugural Face-Off
Contemporary Concepts in Hematologic Oncology
Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer
Clinical
Acute Myeloid Leukemia
Brain Cancer
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Gynecologic Cancer
Hematology
Leukemia
Lung Cancer
Lymphoma
Pediatric Cancers
Skin Cancer
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
Morning Rounds
OncView
Podcasts
Readout 360
Satellite Sessions
Sponsored Media
Training Academy
Year in Review
Conferences
All Journals
For Authors
Tumor Board
Frontline Forum
CME/CE
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Print Subscription
eNewsletter
Advertisement
Breast Cancer
| Kidney Cancer
| Leukemia
| Lymphoma
| Multiple Myeloma
| Non-Small Cell Lung Cancer (NSCLC)
| Small Cell Lung Cancer (SCLC)
| Adverse Effects
| Biomarkers
| Bladder Cancer
| Brain Cancer
| Cervical Cancer
| Colorectal Cancer
| Endometrial Cancer
| Esophageal Cancer
| Gastrointestinal Cancer
| Genitourinary Cancers
| Gynecologic Cancers
| Head & Neck Cancer
| Hematology
| Hormone-related Cancers
| Immunotherapy
| Infection
| Liver Cancer
| Lung Cancer
| Mesothelioma
| Neuroendocrine Tumors
| Oncology
| Ovarian Cancer
| Ovarian Cancer Clincal Consult
| Pancreatic Cancer
| Pediatric Cancers
| Prostate Cancer
| Radiation Oncology
| Sarcoma
| Screening
| Skin Cancer & Melanoma
| Surgery
| Thoracic Malignancies
| Thyroid Cancer
View All >>
  • Adverse Effects
  • Biomarkers
  • Bladder Cancer
  • Brain Cancer
  • Breast Cancer
  • Cervical Cancer
  • Colorectal Cancer
  • Endometrial Cancer
  • Esophageal Cancer
  • Gastrointestinal Cancer
  • Genitourinary Cancers
  • Gynecologic Cancers
  • Head & Neck Cancer
  • Hematology
  • Hormone-related Cancers
  • Immunotherapy
  • Infection
  • Kidney Cancer
  • Leukemia
  • Liver Cancer
  • Lung Cancer
  • Lymphoma
  • Mesothelioma
  • Multiple Myeloma
  • Neuroendocrine Tumors
  • Non-Small Cell Lung Cancer (NSCLC)
  • Oncology
  • Ovarian Cancer
  • Ovarian Cancer Clincal Consult
  • Pancreatic Cancer
  • Pediatric Cancers
  • Prostate Cancer
  • Radiation Oncology
  • Sarcoma
  • Screening
  • Skin Cancer & Melanoma
  • Small Cell Lung Cancer (SCLC)
  • Surgery
  • Thoracic Malignancies
  • Thyroid Cancer

SPOTLIGHT -

Around the Practice
| Between the Lines
| Contemporary Concepts
| Journal
| OncView
| Podcasts
| Readout 360
| 2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates
| CancerNetwork® Inaugural Face-Off
| Contemporary Concepts in Hematologic Oncology
| Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
| Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer

Navigators, Reminders May Improve Follow-Up After Positive Fecal Blood Test

Oct 12, 2017
Leah Lawrence

Follow-up intervention by patient navigators or provider reminders may help to improve the number of patients who undergo colonoscopy after positive fecal blood test results.

Follow-up intervention by patient navigators or provider reminders may help to improve the number of patients who undergo colonoscopy after positive fecal blood test results, according to the results of a review published in Annals of Internal Medicine.

“Timely diagnostic colonoscopy after a positive fecal test result is a critical step on the colorectal cancer screening continuum,” wrote Kevin Selby, MD, of Kaiser Permanente Division of Research in Oakland, California, and colleagues. “Although research has primarily focused on screening completion, fecal testing will not be effective if positive results are not followed.”

With this review, Selby and colleagues evaluated interventions that could improve follow-up rates after positive fecal blood tests. They reviewed 23 studies that reported data from an intervention for colonoscopy follow-up of asymptomatic adults with positive fecal test results. The studies included seven randomized and 16 nonrandomized studies.

Much of the research was of low-quality, the researchers noted, particularly with regard to system-level interventions, such as automated referral, patient registries, and quality improvement efforts. However, the study did reveal moderate evidence that supported the implementation of patient- and provider-level interventions.

The evidence suggested that the use of patient navigators, or individuals who work with patients to counsel and guide them through the barriers associated with cancer care, can increase rates of follow-up colonoscopy. The review included five studies of patient navigation interventions. One study compared usual care with or without the addition of a registered nurse patients navigator. Use of a navigator to help with logistic barriers and to conduct motivational interview resulted in a non-significant but clinically relevant increase in the number of patients completing colonoscopies.

“Patient navigators can provide one-on-one education and individualized reduction of structural barriers,” the researchers wrote. “Cost may be a limiting factor, however: An economic evaluation concluded that patient navigation for the follow-up of abnormal results on cancer screening tests costs an additional $275 per patient (CI, $260 to $290).”

Provider-level interventions that utilize electronic reminders to alert physicians of patients who have not taken adequate action after a positive test result were shown to improve colonoscopy completion from 9 to 25 percentage points.

Based on these results, the researchers concluded that “more research is needed given the critical role of the diagnostic resolution of positive test results in fecal blood-based screening.”

Related Videos
Experts on colorectal cancer
Experts on colorectal cancer
Experts on colorectal cancer
Arvind Dasari, MD, MS, an expert on colorectal cancer
Arvind Dasari, MD, MS, an expert on colorectal cancer
Experts on colorectal cancer
Experts on colorectal cancer
Experts on colorectal cancer
Experts on colorectal cancer
Experts on colorectal cancer
Related Content

FDA Gives Priority Review to Fruquintinib in Metastatic Colorectal Cancer

May 26th 2023

Oncology Peer Review On-The-Go: Minimal Residual Disease–Directed Adjuvant Therapy for Patients With Early-Stage Colon Cancer

November 14th 2022

IMX-110/Tislelizumab Yields Notable Tumor Shrinkage in Two Patients With CRC

May 5th 2023

Oncology Peer Review On-The-Go: Tanios Bekaii-Saab, MD, and Experts Examine Therapy Resistance in CRC

May 24th 2022

Tislelizumab/Chemo Yields Survival Benefit in Advanced Esophageal Cancer

April 25th 2023

Zolbetuximab/mFOLFOX6 Prolongs Survival in Locally Advanced Gastric Cancer

April 21st 2023

FDA Gives Priority Review to Fruquintinib in Metastatic Colorectal Cancer

May 26th 2023

Oncology Peer Review On-The-Go: Minimal Residual Disease–Directed Adjuvant Therapy for Patients With Early-Stage Colon Cancer

November 14th 2022

IMX-110/Tislelizumab Yields Notable Tumor Shrinkage in Two Patients With CRC

May 5th 2023

Oncology Peer Review On-The-Go: Tanios Bekaii-Saab, MD, and Experts Examine Therapy Resistance in CRC

May 24th 2022

Tislelizumab/Chemo Yields Survival Benefit in Advanced Esophageal Cancer

April 25th 2023

Zolbetuximab/mFOLFOX6 Prolongs Survival in Locally Advanced Gastric Cancer

April 21st 2023

FDA Gives Priority Review to Fruquintinib in Metastatic Colorectal Cancer

May 26th 2023

Oncology Peer Review On-The-Go: Minimal Residual Disease–Directed Adjuvant Therapy for Patients With Early-Stage Colon Cancer

November 14th 2022

IMX-110/Tislelizumab Yields Notable Tumor Shrinkage in Two Patients With CRC

May 5th 2023

Oncology Peer Review On-The-Go: Tanios Bekaii-Saab, MD, and Experts Examine Therapy Resistance in CRC

May 24th 2022

Tislelizumab/Chemo Yields Survival Benefit in Advanced Esophageal Cancer

April 25th 2023

Zolbetuximab/mFOLFOX6 Prolongs Survival in Locally Advanced Gastric Cancer

April 21st 2023
Related Content

Data from the phase 3 FRESCO and FRESCO-2 trials support the new drug application for fruquintinib as a treatment for patients with previously treated metastatic colorectal cancer.

FDA Gives Priority Review to Fruquintinib in Metastatic Colorectal Cancer

May 26th 2023
Article

Data from the phase 3 FRESCO and FRESCO-2 trials support the new drug application for fruquintinib as a treatment for patients with previously treated metastatic colorectal cancer.


Lead author Ibrahim Halil Sahin, MD, spoke with CancerNetwork® about his work investigating postoperative circulating tumor DNA dynamics in early-stage colon cancer as part of the CIRCULATE-US trial published in the journal ONCOLOGY®.

Oncology Peer Review On-The-Go: Minimal Residual Disease–Directed Adjuvant Therapy for Patients With Early-Stage Colon Cancer

November 14th 2022
Podcast

Lead author Ibrahim Halil Sahin, MD, spoke with CancerNetwork® about his work investigating postoperative circulating tumor DNA dynamics in early-stage colon cancer as part of the CIRCULATE-US trial published in the journal ONCOLOGY®.


Combination treatment with IMX-110 and tislelizumab yields no dose-limiting toxicities thus far in the first cohort of patients with advanced/metastatic colorectal cancer in the phase 1b/2a IMMINENT-01 trial.

IMX-110/Tislelizumab Yields Notable Tumor Shrinkage in Two Patients With CRC

May 5th 2023
Article

Combination treatment with IMX-110 and tislelizumab yields no dose-limiting toxicities thus far in the first cohort of patients with advanced/metastatic colorectal cancer in the phase 1b/2a IMMINENT-01 trial.


Oncology Peer Review On-The-Go: Tanios Bekaii-Saab, MD, and Experts Examine Therapy Resistance in CRC

Oncology Peer Review On-The-Go: Tanios Bekaii-Saab, MD, and Experts Examine Therapy Resistance in CRC

May 24th 2022
Podcast

Tanios Bekaii-Saab, MD, talks with Kristen Ciombor, MD, MSCI, and John Strickler, MD, about targeted therapy resistance, rechallenge, and acquired resistance mutations in colorectal cancer.


Investigators report that patients with advanced or metastatic esophageal squamous cell carcinoma had superior overall survival benefit following treatment with tislelizumab/chemotherapy vs placebo/chemotherapy.

Tislelizumab/Chemo Yields Survival Benefit in Advanced Esophageal Cancer

April 25th 2023
Article

Investigators report that patients with advanced or metastatic esophageal squamous cell carcinoma may have superior overall survival benefit following treatment with tislelizumab/chemotherapy vs placebo/chemotherapy.


Patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma may experience significant survival benefit following treatment with zolbetuximab.

Zolbetuximab/mFOLFOX6 Prolongs Survival in Locally Advanced Gastric Cancer

April 21st 2023
Article

Patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma may experience significant survival benefit following treatment with zolbetuximab.

About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.